Successfully engrafted mice with comparable disease load (percent CD19+/CD5+ B cells in the blood) were randomly assigned to receive ibrutinib or vehicle by daily oral gavage at any given enrollment time to control for different growth kinetics of the engrafted tumor cells. Here, CD5 is linked to neoplasm.